IMPORTANCE Mutations in APP,PSEN1, and PSEN2 lead to early-onset Alzheimer disease (EOAD) but account for only approximately 11% of EOAD overall, leaving most of the genetic risk for the most severe form of Alzheimer disease unexplained. This extreme phenotype likely harbors highly penetrant risk variants, making it primed for discovery of novel risk genes and pathways for AD.
E arly-onset Alzheimer disease (EOAD), commonly defined as having age-at-onset (AAO) AD before age 65 years, accounts for approximately 10% of all cases of AD. 1 Rare mutations (minor allele frequency <0.001) in APP (351 Entrez Gene), PSEN1 (5663 Entrez Gene), and PSEN2 (5664 Entrez Gene) are the main genetic risk factors for EOAD, 2 which has a prevalence estimated as 54 per 100 000 individuals aged 30 to 65 years, and 98 per 100 000 of those aged 45 to 64 years. 3 The highly penetrant mutations in these genes account for 60% to 70% of familial EOAD and 5% to 10% of EOAD overall, leaving the majority of genetic risk for this most severe form of AD unexplained. Identifying additional loci harboring highly penetrant, rare risk variants for EOAD has been challenging, although research implicates late-onset AD (LOAD) risk genes, such as SORL1 (6653 Entrez Gene) 4 and TREM2 (54209 Entrez Gene), [5] [6] [7] in the development of EOAD, highlighting the potential for shared genes and pathways between the early and late forms of AD. This shared genetic architecture is likely, given their similar pathology 8, 9 and the arbitrary nature of the commonly used criterion of AAO younger than 65 years delineatingEOADfromLOAD. Analysis of EOAD, which has a strong genetic component, should enhance identification of additional AD risk loci as these cases likely harbor rare, highly penetrant risk variants for disease, whereas the more common late-onset phenotype is expected to have a more complex genetic architecture. [10] [11] [12] Following this hypothesis, we performed whole-exome sequencing (WES) in 51 non-Hispanic white (NHW) individuals with EOAD (previously screened negative for known EOAD risk variants in APP, PSEN1, and PSEN2)to search for rare variants contributing to the risk for EOAD. Variant filtering for heterozygous functional rare variants was performed to identify high-priority variants and genes. Identified candidate variants and genes underwent additional testing in large EOAD and LOAD case-control data sets.
Methods

WES of EOAD Cases Selection of EOAD Cases for Sequencing
Familial and sporadic NHW patients with EOAD with AAO younger than 65 years (mean, 54 years; range, 44-64 years) and thus potentially fitting the profile of either APP, PSEN1,o r PSEN2 cases were sequenced for established mutations in these genes on ascertainment to eliminate individuals with known causative genetic factors. Individuals with apolipoprotein E (APOE) (348 Entrez Gene) ε4/4 status, which can exhibit AAO as early as 65 years, 13 were also excluded from sequencing. In total, 51 NHW patients with EOAD were selected for WES from the John P. Hussman Institute for Human Genomics and Case Western Reserve University Alzheimer Disease Cohort (eTable 1i nt h eSupplement provides details). The study was conducted from January 21, 2013, to October 13, 2016 . All cognitively impaired individuals, including any who changed affection status, were evaluated by the John P. Hussman Institute for Human Genomics AD clinical staff, which includes 3 of us: a geriatric psychiatrist (R.M.C.), a neurologist (J.M.V.), and a neuropsychologist (M.L.C.). In addition, 53 individuals (42 with EOAD; 11 unaffected individuals), from 19 Caribbean Hispanic families were selected for WES with mean AAO of 55 years. These families were screened for the absence of APP, PSEN1, PSEN2, MAPT (4137 Entrez Gene), and GRN (2896 Entrez Gene) mutations (eTable 1 in the Supplement). All affected individuals met the internationally recognized standard National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS/ADRA) criteria for AD. 14 The institutional review boards at University of Miami's Human Subject Research Office, Columbia University's Human Research Protection Office, and Vanderbilt University Medical Center approved all study procedures, and written informed consent was obtained from all study participants; the participants received financial compensation.
WES, Variant Calling and Quality Control
Variants were normalized using BCFTools 15, 16 and variants with read depth less than 10, variant quality score log-odds less than 0, genotype quality less than 20, and 20 base pair genome mappability scores less than 1 from the Duke Uniqueness Track 17 were removed from further analysis. Reported variants were confirmed with Sanger sequencing. Further details of the WES protocol can be found in the eMethods in the Supplement.
WES Variant Prioritization
Variant Filtering for Rare Nonsynonymous or Loss-of-Function Variants Filtering of WES variants prioritized for follow-up association testing was performed using KGGSeq 18 and custom perl and bash scripts. Nonsynonymous or loss-of-function variants with a global minor allele frequency of 0.001 or less that were in a heterozygous state and showed autosomaldominant or X-linked dominant segregation in families, or existed in a heterozygous state in nonfamilial cases, were selected ( Figure 1) . Deleteriousness of these variants was assessed using Combined Annotation Dependent Depletion (CADD) scores. 19 A detailed description of the filtering steps imple-minor allele frequency cutoff based on a maximum allele frequency calculation, is provided in the eMethods in the Supplement.
Prioritization of Variants in Known or Suspected AD Genes
After filtering on the criteria above, we first investigated variation in well-established and recently associated EOAD risk genes (APP, PSEN1, PSEN2, SORL1, and TREM2) and genes previously linked to EOAD (MAPT and GRN), ). Clinical significance of identified variants in these genes was assessed using the ClinVar Database on June 29, 2015.
32 Cases carrying known pathogenic variants were excluded from further analysis for novel genes.
Prioritization of Variants in Novel Candidate Genes
The remaining variants in individuals without a known pathogenic mutation were then prioritized for follow-up in the Alzheimer Disease Genetic Consortium (ADGC) EOAD association study, using the following criteria: 
Association Testing of Prioritized Variants and Genes
Prioritized variants and genes, both known and novel, were tested for association with EOAD and LOAD in a large casecontrol cohort from the ADGC. 
Cohort Description
Results
Variants in Known EOAD Genes
Several rare nonsynonymous or loss-of-function mutations in known or suspected EOAD genes were identified in our case series ( Table 1) . The SORL1 missense mutations were identified in 3 families, 2 of which also have family members with LOAD. Two of these mutations, T588I (present in 4 affected individuals) and T2134M (present in 3 affected individuals) are mutations in the same individuals reported by Cuccaro et al. 36 A third mutation, a novel frameshift variant (Cys1431fs), was identified in 2 sisters, 1 who is APOEε3/4 affected with AAO of 60 years and the other with mild cognitive impairment (age at examination, 69 years; APOEε3/3). A PSEN1 missense mutation (A79V) previously reported in a LOAD family and classified as pathogenic by ClinVar was identified in 2 individuals with AAO of 54 years (APOEε3/4) and 56 years (APOEε3/4). 37 An additional PSEN1 missense mutation was identified in a patient with AAO of 50 years (APOEε3/ 3), and a PSEN2 start-loss mutation (rs61757781) was present in an individual with AAO of 48 years (APOEε3/3). MAPT R406W, previously reported in both frontotemporal dementia with parkinsonism-17 38,39 and AD, [24] [25] [26] was shared by 2 siblings and an unrelated participant. The individuals with the MAPT R406W and PSEN1 A79V mutations were removed from further analyses owing to their ClinVar pathogenic classification. All other variants were novel or rated as probable nonpathogenic or untested in ClinVar (Table 1 ). Only 1 of the known EOAD gene variants was available from the ADGC exome chip study, a start-loss mutation in PSEN2 (rs1757781), which showed no evidence for association in the EOAD or LOAD sample. Twenty-six rare variants, 16 of which are deleterious according to CADD (eTable 3 in the Supplement), were present in known or suspected LOAD genes in our EOAD case series, including a frameshift variant in HLA-DRB1 (3123 Entrez Gene) and missense variants in ABCA7 (10347 Entrez Gene), AKAP9 (10142 Entrez Gene), CD2AP (23607 Entrez Gene), EPHA1 (2041 Entrez Gene), MS4A4A (51338 Entrez Gene), RIN3 (79890 Entrez Gene), and UNC5C. Five of the known LOAD variants were on the exome chip, including a rare RIN3 missense variant (rs150221413), which showed suggestive evidence of association with EOAD at a Bonferroni correction level of P = .01 for 5 variants tested (odds ratio [OR], 4.56 (95% CI, 1.26-16.48; P = .02 without adjustment for APOE, Bonferroni-corrected P value (BP) = 0.091; P =. 024withAPOE adjustment) and, although not significant, was more frequent in LOAD cases than controls (minor allele frequency, 0.0008 and 0.0004 in cases vs controls, respectively; OR, 1.79; 95% CI, 0.65-4.87; P = .23, BP>.99) ( Table 2 ;eTable4intheSupplement reports secondary model results).
Genomic control inflation factors (GIFs) and quantilequantile plots show that our analyses are not inflated and are valid or conservative (ie, the EOAD single-variant tests) in terms of distribution of results (GIF<1. 
Novel Candidate Variants and Genes Variants Present in Multiple Unrelated Cases
After removing variants in highly mutable genes (based on high gene damage index scores), 108 rare deleterious variants in 106 genes were present in 2 or more unrelated individuals. Of these, 43 variants were testable in the ADGC exome chip data set. A missense variant in RUFY1 (80230 Entrez Gene), present in 4 ADGC association cases and no controls, showed evidence of an association with EOAD (OR, 18.63; 95% CI, 1.62-213.45; P = .003, BP=.129), nearing a Bonferroni-corrected significance level of P =1×10 −3 for 43 variants tested (Table 2 ; eTable 4 in the Supplement provides secondary model results). All variants occurredincases(4EOADand3LOAD),with3of4EOADpatients carrying APOE ε4 (P = .28) and 1 patient with LOAD carrying APOEε4 (P = .07). The rarity of the variant makes it difficult to conclude whether the effect in EOAD is spurious or due to a chance correlation between APOEε4 and the RUFY1 variant. Four other variants, including a missense variant present in 2 WES EOAD cases in the gene NAA60, showed nominal significance in the ADGC data set (eTable 5 in the Supplement).
Genes With Variants in Multiple Unrelated Cases
Filtering to genes with rare, deleterious nonsynonymous or loss-of-function variants in multiple unrelated individuals left 747 genes, 676 of which were testable in the ADGC EOAD association study (Bonferroni-critical P =7 .40×10 −5 for 676 genes tested). The gene PSD2 (84249 Entrez Gene) met genome-wide significance in both EOAD (P =2. 05×10 −6 , BPsig = 1 . 3×1 0 −3 , APOE-adjusted P =1 . 5 5×1 0 −5 ) and LOAD (P =6.22×10 −6 ,BP=4.1×10 −3 , APOE-adjusted P =2.30×10 −4 ) cohorts when all variants in the gene were included in a genebased test. The APOE-adjusted results are slightly less signifi- Following a hypothesis that rare functional variants are responsible for EOAD, we filtered WES data on 53 NHW patients with EOAD based on consequence, deleteriousness, ethnic-specific (which have been shown to aid in the identification of true causal disease variants 51 ), and population-specific minor allele frequencies. In addition to identifying several known and novel mutations in known or suspected EOAD genes (GRN, MAPT, PSEN1, PSEN2, SORL1, and TREM2), we report several candidate genes for EOAD involved in the endolysosomal pathway, including RUFY1, PSD2, TCIRG1, and the known LOAD risk gene RIN3 (Table 2) . These results adjusted for principal components only, but were supported for PSD2 in secondary analyses adjusting for age, sex, and principal components (P =1.23×10 −3 ); however, these analyses do not show an association in the other candidate genes (eTable 4 in the Supplement), possibly due to the older mean age of the control participants. In addition, although PSD2, TCIRG1, and RIN3 are associated with AD even with adjustment for APOE, the rarityoftheRUFY1 variant, which occurs only in AD, makes its evaluation in APOE-adjusted analysis difficult. All 4 genes participate in different steps of the endolysosomal pathway, highlighting the likelihood that alterations in many endocytic genes can increase the risk of EOAD.
The PSD2 gene appears to play an early role through its synthesis of phospholipids critical to maturation of transport vesicles and vacuoles integral to the pathway. 52 Disturbance of the formation of these vesicles and vacuoles is critical in proper processing of endosomal debris. The importance of PSD2 to AD in this process potentially revolves around the formation and proper maintenance of phosphatidylethanolamine, a function for which PSD2 is essential. 53 This enzyme, which is decreased in AD brains, 54 has been shown to regulate the γ-secretase activity integral to APP processing 55 and to positively regulate autophagy and longevity in yeast.
56
Both RUFY1, which binds vesicles containing the endosomal traffic regulator phosphatidylinositol-3-phosphate, 57 and RIN3, a known LOAD risk gene, appear to be critical to the development and regulation of the early endosome, a major site of Aβ peptide generation that is markedly enlarged within neu- Through association analysis of our candidate genes in a large AD cohort from the ADGC, we also add to accumulating evidence pointing to overlap of risk genes involved in both EOAD and LOAD, with both TCIRG1 and PSD2 associated with EOAD and LOAD. This overlap of genetic architecture between the early-and late-onset forms of the disease has been previously identified for the genes SORL1, TREM2, and PSEN1.
66 In addition, the ε4 allele of APOE, the strongest genetic risk factor for LOAD, also drives the risk for EOAD in ε4/ε4 individuals with AAO of approximately 65 years and accentuates endosome pathology at early stages of AD, 58 a finding that is in line with other evidence pointing toward endolysosomal pathology occurring in the early stages of AD and promoting earlier onset of AD. 50 In addition, although some differences in neuropathology of EOAD and LOAD have been identified, many pathologic features overlap between the early and late forms of AD.
67
Limitations
There are several limitations to our study. First, some variants prioritized in the WES analysis were not present on the exome chip, making assessment of their impact impossible in the present study. These variants should be further examined in large, case-control association studies to determine their potential risk to AD. Second, although we followed up our prioritized WES variants in a sizeable case-control sample, the power of this sample for assessment of very rare variants is limited, and replication of these results in other large casecontrol samples will be necessary. Finally, while several studies suggest that our top results are involved in endolysosomal transport, additional wet-laboratory studies will need to confirm that this pathway is the mechanism through which these genes increase the risk for AD.
Conclusions
Using a combined strategy of bioinformatics filtering of WES of EOAD cases, followed by testing of prioritized variants and genes in a large EOAD and LOAD cohort, we have identified several novel EOAD candidate genes, 2 of which were also associated with LOAD. Taken together, our results highlight endolysosomal alterations in multiple genes as risk factors for EOAD and point to additional genes conferring risk of both EOAD and LOAD. 
